Aetion’s Lowell Schiller, Chief Legal and Regulatory Officer, participated in a workshop sponsored by Avalere Health and Merck to discuss innovative methods and tools adopted by regulators during the COVID-19 pandemic, and how they should be used going forward. These included tools and regulatory agilities to accelerate evidence generation, including advances in the use of real-world evidence, to accelerate the development of vaccines and therapeutics without compromising quality, safety, or efficacy. Many of these approaches, including advances in RWE, will benefit patients, developers, and the public health in many contexts outside the pandemic setting.

We are honored that Aetion’s work with FDA was featured as a case study in this workshop, showcasing Aetion’s role in advancing the use of RWE during the COVID-19 pandemic.